As Biogen awaits an FDA decision on its controversial Alzheimer's disease hopeful aducanumab, the company is setting the stage for an entry into the hot gene therapy field. Biogen has drawn up plans for a new gene therapy manufacturing facility at its Research Triangle Park campus in North Carolina. The 175,000-square-foot facility will be designed to scale up the manufacturing of the products that are in Biogen's growing gene therapy pipeline. Biogen expects the facility to be up and running by 2023. The company will invest some $200 million in the new site, with plans to add about 90 new jobs to its current Research Triangle Park workforce of 1,900. The expansion comes as Biogen searches for revenue sources to pick up the slack from declining sales of its spinal muscular atrophy blockbuster Spinraza and multiple sclerosis drug Tecfidera. The company is expecting the FDA to rule on aducanumab in June, but it will most definitely need more blockbuster prospects. Biogen do